The histone deacetylase (HDAC) inhibitor valproate has been shown to act synergistically with fludarabine and cladribine, two clinically used anticancer drugs in the treatment of CLL cells41. Here, HDAC9 is linked to B-cell chronic lymphocytic leukemia.